It binds to its ligands CD155 (PVR) or NECTIN-2 (CD112), which are frequently overexpressed on malignant or antigen-presenting cells (APCs), TIGIT suppresses cytotoxic immune responses, contributing to immune evasion within the tumor microenvironment (TME) (17, 18). Here, PVR is linked to neoplasm.